Genesys Capital (@GenesysCapital) header
Genesys Capital (@GenesysCapital) profile picture

Early-Stage Life Science Venture Capital Investor

Toronto
Joined February 2014
Photo by Genesys Capital (@GenesysCapital)Photo by Genesys Capital (@GenesysCapital)Photo by Genesys Capital (@GenesysCapital)Photo by Genesys Capital (@GenesysCapital)Photo by Genesys Capital (@GenesysCapital)Photo by Genesys Capital (@GenesysCapital)Photo by Genesys Capital (@GenesysCapital)Photo by Genesys Capital (@GenesysCapital)Photo by Genesys Capital (@GenesysCapital)Photo by Genesys Capital (@GenesysCapital)
Big News from Genesys Capital! We’re thrilled to unveil our brand new logo and revamped website! 🎉 Check out the new site here: genesyscapital.com
4
143
Team Genesys is heading for the 25th time to the #JPM25. The weather forecast looks better than the last year's & we hope that this lifts sentiments across the life sci sector Also, Genesys originated company @ProfoundMedical will be presenting for the 1st time at JPM this year.
3
434
Toronto host Taylor’s ERAS tour, we're posting our ERAS poster REPUTATION ERA reflects top-decile DPI w/ exits of Fusion Pharma & Inversago (US$3.5B), & we’re still not done yet – stay tuned for Flosonics/Questat/Veralox Embarking on our EVERMORE ERA - get your tix today🍁
1
3
2,344
Novo announces Monlunabant (Inversago’s INV-202) Phase 2a data in obesity, with significant weight loss after 16 weeks of treatment (7.1 kg with a once daily 10 mg dose). Based on the results, Novo expects to initiate a larger Phase 2b trial in 2025 novonordisk.com/content/nnco…
2
186
Genesys is closing out a fantastic week at this year’s @MorganStanley Healthcare Conference in NYC. A highlight for us was hearing @novonordisk's excitement about Monlunabant, acquired from @inversago last year, and its potential to change the landscape of metabolic disease!
2
1
6
6,499
With Genesys’ funding, Feldan aims to develop a first-in-class non-invasive intralesional treatment for basal cell carcinoma. We are very excited to be part of Feldan’s “drug delivery platform” mission and it’s an excellent addition to our newest Fund. newswire.ca/news-releases/fe…
1
4
315
Last month, Fusion Pharmaceuticals exited to AstraZeneca for $2.4 Billion USD - a Genesys co-creation that has become a Canadian anchor company and global hub of radiopharma excellence. Check out the origin story below. linkedin.com/feed/update/urn…
3
159
Congrats to our very own Damian Lamb for being recognized with a 2024 Alumnus Award from McMaster University! Damian has been committed to supporting the commercialization of McMaster's world-class research for many years #FusionPharma #CPDC alumni.mcmaster.ca/s/1439/22…
1
114
Congratulations to Genesys Partner and CFO Jennifer Williams on being appointed to the Board of the @cvca ! Proud to have Genesys Capital represented!
1
6
440
Fusion Pharma reveals early Ph2 data from FPI-2265 at #AACR2024 "PSA50 of 50% Exceeds Expectations; Uptake Response and Post-Pluvicto Activity Encouraging; Safety in Line With Previous Data" Andy T. Hsieh, Ph.D. at William Blair Link to the poster - qrcodes.pro/y32gAO
3
234
Origin Story of Fusion Pharmaceuticals $FUSN Last week Genesys portfolio company @FusionPharmaInc announced its acquisition by @AstraZeneca! Check out our contributions to this Canadian success story below
2
6
4,936
No better guest speaker than Genesys' Jamie Stiff for a lecture on "EXITS" - especially as Genesys had US$3.5 Billion in exits since last fall Kudos to @cvca & @iveybusiness to put together such a good event - CPCIS Program (Canadian Private Capital Investment School)
1
4
406
Good news keeps on flowing here at Genesys: Flosonics secures US$20M Series C to accelerate growth. Led by @nlvpartners , with participation from previous investors @ArboretumVC, Genesys Capital & @iganvc Congrats to Joe Eibl & @Flosonics team! flosonicsmedical.com/flosoni…
2
5
348
BREAKING: Our co-creation exits now totaling US$3.5B in <12 months: $FUSN to be acquired by $AZN for $2.4B Congrats to John Valliant & @FusionPharmaInc team! Damian Lamb was the inaugural Chairman of the Board, from company creation through IPO. ir.fusionpharma.com/2024-03-…
1
2
6
5,433
As we await FUSION PHARMA $FUSN to reveal its interim data from the Phase 2 TATCIST Clinical Trial evaluating FPI-2265 at the 2024 AACR in April, RBC did an amazing job in providing RadioPharma landscape (below image from the recent report titled: Radiopharma on the Rise)
7
2
31
22,350